Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench.
Hui
Chi-Hung
CH
Haematology Division, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia. chi-hung.hui@imvs.sa.gov.au
Hughes
Timothy P
TP
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000078224:Lenograstim; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D014182:Transplantation, Autologous
D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D016315:Proto-Oncogene Proteins c-abl